Bicara Therapeutics to Present at Upcoming November Investor Conferences
CAMBRIDGE, Mass., November 8, 2021 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that company leadership will participate in two upcoming virtual investor conferences in November:
Stifel 2021 Virtual Healthcare Conference
Format: Live presentation
Date: Monday, November 15, 2021
Time: 10:40 – 11:10 a.m. ET
Piper Sandler 33rd Annual Virtual Healthcare Conference
Format: On-demand presentation
Date: Monday, November 22, 2021
Time: 10:00 a.m. ET
About Bicara Therapeutics:
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/2 study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy.
Contacts:
Investors
Sarah McCabe
Stern Investor Relations, Inc.
[email protected]
212-362-1200
Media
Chris Railey
Ten Bridge Communications
[email protected]
617-834-0936